Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies - a EuroFlow study

MWC. Verbeek, C. Buracchi, A. Laqua, S. Nierkens, L. Sedek, J. Flores-Montero, M. Hofmans, E. Sobral de Costa, M. Nováková, E. Mejstrikova, S. Barrena, S. Kohlscheen, M. Szczepanowski, J. Kulis, E. Oliveira, R. Jugooa, AX. de Jong, T....

. 2022 ; 197 (1) : 76-81. [pub] 20211208

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22018914

The standardized EuroFlow protocol, including CD19 as primary B-cell marker, enables highly sensitive and reliable minimal residual disease (MRD) assessment in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) patients treated with chemotherapy. We developed and validated an alternative gating strategy allowing reliable MRD analysis in BCP-ALL patients treated with CD19-targeting therapies. Concordant data were obtained in 92% of targeted therapy patients who remained CD19-positive, whereas this was 81% in patients that became (partially) CD19-negative. Nevertheless, in both groups median MRD values showed excellent correlation with the original MRD data, indicating that, despite higher interlaboratory variation, the overall MRD analysis was correct.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018914
003      
CZ-PrNML
005      
20220804135200.0
007      
ta
008      
220720s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bjh.17992 $2 doi
035    __
$a (PubMed)34881427
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Verbeek, Martijn W C $u Laboratory for Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands $1 https://orcid.org/0000000272405176
245    10
$a Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies - a EuroFlow study / $c MWC. Verbeek, C. Buracchi, A. Laqua, S. Nierkens, L. Sedek, J. Flores-Montero, M. Hofmans, E. Sobral de Costa, M. Nováková, E. Mejstrikova, S. Barrena, S. Kohlscheen, M. Szczepanowski, J. Kulis, E. Oliveira, R. Jugooa, AX. de Jong, T. Szczepanski, J. Philippé, JJM. van Dongen, A. Orfao, M. Brüggemann, G. Gaipa, VHJ. van der Velden
520    9_
$a The standardized EuroFlow protocol, including CD19 as primary B-cell marker, enables highly sensitive and reliable minimal residual disease (MRD) assessment in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) patients treated with chemotherapy. We developed and validated an alternative gating strategy allowing reliable MRD analysis in BCP-ALL patients treated with CD19-targeting therapies. Concordant data were obtained in 92% of targeted therapy patients who remained CD19-positive, whereas this was 81% in patients that became (partially) CD19-negative. Nevertheless, in both groups median MRD values showed excellent correlation with the original MRD data, indicating that, despite higher interlaboratory variation, the overall MRD analysis was correct.
650    _2
$a adaptorové proteiny signální transdukční $7 D048868
650    _2
$a antigeny CD19 $x terapeutické užití $7 D018941
650    12
$a Burkittův lymfom $7 D002051
650    _2
$a průtoková cytometrie $x metody $7 D005434
650    _2
$a lidé $7 D006801
650    _2
$a reziduální nádor $7 D018365
650    12
$a pre-B-buněčná leukemie $x diagnóza $x farmakoterapie $7 D015452
650    12
$a akutní lymfatická leukemie $7 D054198
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Buracchi, Chiara $u Tettamanti Research Center, Pediatric Clinic University of Milano Bicocca, Monza (MB), Italy
700    1_
$a Laqua, Anna $u Department of Hematology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany
700    1_
$a Nierkens, Stefan $u Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
700    1_
$a Sedek, Lukasz $u Department of Microbiology and Immunology, Medical University of Silesia in Katowice, Zabrze, Poland $u Department of Pediatric Hematology and Oncology, Zabrze, Medical University of Silesia in Katowice, Katowice, Poland
700    1_
$a Flores-Montero, Juan $u Translational and Clinical Research program, Cancer Research Centre (IBMCC, CSIC-USAL), Cytometry Service, NUCLEUS, Salamanca, Spain $u Department of Medicine, University of Salamanca (USAL), Salamanca, Spain $u Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain $u Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
700    1_
$a Hofmans, Mattias $u Department of Diagnostic Sciences, Ghent University, Ghent, Belgium $u Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium
700    1_
$a Sobral de Costa, Elaine $u Pediatrics Institute IPPMG, Faculty of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
700    1_
$a Nováková, Michaela $u CLIP-Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
700    1_
$a Mejstrikova, Ester $u CLIP-Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic $1 https://orcid.org/0000000151694653
700    1_
$a Barrena, Susana $u Translational and Clinical Research program, Cancer Research Centre (IBMCC, CSIC-USAL), Cytometry Service, NUCLEUS, Salamanca, Spain $u Department of Medicine, University of Salamanca (USAL), Salamanca, Spain $u Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain $u Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
700    1_
$a Kohlscheen, Saskia $u Department of Hematology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany
700    1_
$a Szczepanowski, Monika $u Department of Hematology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany
700    1_
$a Kulis, Jan $u Department of Microbiology and Immunology, Medical University of Silesia in Katowice, Zabrze, Poland $u Department of Pediatric Hematology and Oncology, Zabrze, Medical University of Silesia in Katowice, Katowice, Poland
700    1_
$a Oliveira, Elen $u Pediatrics Institute IPPMG, Faculty of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
700    1_
$a Jugooa, Romana $u Laboratory for Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
700    1_
$a de Jong, Anja X $u Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
700    1_
$a Szczepanski, Tomasz $u Department of Microbiology and Immunology, Medical University of Silesia in Katowice, Zabrze, Poland $u Department of Pediatric Hematology and Oncology, Zabrze, Medical University of Silesia in Katowice, Katowice, Poland $1 https://orcid.org/000000015336261X
700    1_
$a Philippé, Jan $u Department of Diagnostic Sciences, Ghent University, Ghent, Belgium $u Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium
700    1_
$a van Dongen, Jacques J M $u Department of Immunohematology and Blood Transfusion (IHB), University Medical Center (LUMC), Leiden, the Netherlands
700    1_
$a Orfao, Alberto $u Translational and Clinical Research program, Cancer Research Centre (IBMCC, CSIC-USAL), Cytometry Service, NUCLEUS, Salamanca, Spain $u Department of Medicine, University of Salamanca (USAL), Salamanca, Spain $u Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain $u Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain $1 https://orcid.org/0000000200077230
700    1_
$a Brüggemann, Monika $u Department of Hematology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany
700    1_
$a Gaipa, Giuseppe $u Tettamanti Research Center, Pediatric Clinic University of Milano Bicocca, Monza (MB), Italy
700    1_
$a van der Velden, Vincent H J $u Laboratory for Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands $1 https://orcid.org/0000000194573763
773    0_
$w MED00009374 $t British journal of haematology $x 1365-2141 $g Roč. 197, č. 1 (2022), s. 76-81
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34881427 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804135154 $b ABA008
999    __
$a ok $b bmc $g 1822485 $s 1170157
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 197 $c 1 $d 76-81 $e 20211208 $i 1365-2141 $m British journal of haematology $n Br J Haematol $x MED00009374
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Možnosti archivace